← feed

Is NCT03130556 results overdue?

Yes — results are overdue. Primary completion was 2017-07-06; the FDAAA-801 reporting deadline (2018-07-06) passed 2907 days ago and no results are posted on ClinicalTrials.gov.

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT IDNCT03130556 ↗
SponsorPfizer (INDUSTRY)
Public issuerPFIZER INC — PFE (CIK 0000078003) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-07-06 (ACTUAL)
Reporting deadline2018-07-06 (completion + 365d)
Days overdue2907
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 ddbad7b8ad73b7e8… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03130556. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →